NASDAQ:FWBI First Wave BioPharma (FWBI) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$2.60▼$4.6352-Week Range N/AVolume56,500 shsAverage Volume212,944 shsMarket Capitalization$7.34 millionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesShort InterestTrends Get First Wave BioPharma alerts: Email Address Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetArtificial Intelligence has revolutionized the way we consume media and entertainment… And the A.I. wave has also created MASSIVE opportunities for savvy investors. One recent move stands out above all others: recently surfaced investments from three major media companies.Click here for all the details… About First Wave BioPharma Stock (NASDAQ:FWBI)First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.Read More Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetArtificial Intelligence has revolutionized the way we consume media and entertainment… And the A.I. wave has also created MASSIVE opportunities for savvy investors. One recent move stands out above all others: recently surfaced investments from three major media companies.Click here for all the details… FWBI Stock News HeadlinesMay 22, 2024 | finance.yahoo.comEntero Therapeutics to Present Corporate Update at 2024 BIO International ConventionMay 20, 2024 | finance.yahoo.comEntero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) ConferenceJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 16, 2024 | finance.yahoo.comFirst Wave BioPharma Changes Name to Entero TherapeuticsMay 15, 2024 | investorplace.comFWBI Stock Earnings: First Wave BioPharma Beats EPS for Q1 2024May 10, 2024 | globenewswire.comFirst Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-MarketMay 9, 2024 | globenewswire.comFirst Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness MonthApril 24, 2024 | globenewswire.comFirst Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, NutrientsJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” April 17, 2024 | finance.yahoo.comFirst Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap ShowcaseApril 15, 2024 | globenewswire.comFirst Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders ConferenceApril 5, 2024 | investing.comFirst wave BioPharma CEO sells shares to cover tax obligationsMarch 21, 2024 | investing.comFirst wave BioPharma CFO sells shares worth over $5,500March 21, 2024 | investing.comFirst wave BioPharma CEO sells shares worth over $9,000March 18, 2024 | globenewswire.comFirst Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) ConferenceMarch 14, 2024 | investorplace.comWhy Is First Wave BioPharma (FWBI) Stock Up Today?March 14, 2024 | msn.comFirst Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac DiseaseMarch 14, 2024 | globenewswire.comFirst Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical PipelineSee More Headlines Receive FWBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today7/07/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FWBI CUSIPN/A CIK1604191 Webwww.azurrx.com Phone(561) 589-7020FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$36.00 Low Stock Price Target$36.00 Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-102.83% Return on Assets-22.74% Debt Debt-to-Equity Ratio0.40 Current Ratio1.21 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.54 per share Price / BookN/AMiscellaneous Outstanding Shares2,480,000Free Float2,463,000Market Cap$7.34 million OptionableNot Optionable Beta1.28 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. James R. Sapirstein M.B.A. (Age 63)R.Ph., CEO & Chairman Comp: $906.2kMs. Sarah Romano CPA (Age 43)Chief Financial Officer Comp: $624.88kDr. Jack A. Syage Ph.D. (Age 69)President, COO & Director Ms. Amy Chandler-Skerkis (Age 55)Vice President of Regulatory Affairs, QA & Compliance Mr. Martin Krusin M.B.A.Senior Vice President of Corporate DevelopmentKey CompetitorsPulmatrixNASDAQ:PULMLisata TherapeuticsNASDAQ:LSTAEnlivex TherapeuticsNASDAQ:ENLVBolt BiotherapeuticsNASDAQ:BOLTRenovoRxNASDAQ:RNXTView All CompetitorsInsidersJames SapirsteinSold 174 sharesTotal: $736.02 ($4.23/share)Sarah RomanoSold 75 sharesTotal: $317.25 ($4.23/share)James SapirsteinSold 1,887 sharesTotal: $9,359.52 ($4.96/share)Sarah RomanoSold 1,120 sharesTotal: $5,555.20 ($4.96/share)James SapirsteinSold 166 sharesTotal: $697.20 ($4.20/share)View All Insider Transactions FWBI Stock Analysis - Frequently Asked Questions How were First Wave BioPharma's earnings last quarter? First Wave BioPharma, Inc. (NASDAQ:FWBI) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($13,734.00) EPS for the quarter, missing analysts' consensus estimates of ($3,318.00) by $10,416.00. When did First Wave BioPharma's stock split? Shares of First Wave BioPharma reverse split on Monday, December 18th 2023. The 1-20 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. This page (NASDAQ:FWBI) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Wave BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share First Wave BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.